| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.3 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.044 | 0.3 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.3 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.055 | 0.3 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.044 | 0.3 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.033 | 0.3 |